鼻咽癌原发灶与自身颈部淋巴结转移癌组织中上上皮型钙黏附蛋白和β-链接素的表达差异  

Expressions of E-Cadherin and β-catenin in primary nasopharyngeal carcinoma and self cervical lymph node metastasis carcinoma

作　　者：梁玉莹[1] 黎静[1] 王卓才[2] 赖日权[2] 

机构地区：[1]广州军区广州总医院肿瘤科 [2]广州军区广州总医院病理科,510010

出　　处：《实用医学杂志》2007年第22期3509-3511,共3页The Journal of Practical Medicine

摘　　要：目的:研究鼻咽癌原发灶和自身颈部淋巴结转移癌组织中上皮型钙黏附蛋白(E-Cadherin)和β-链接素(β-catenin)表达水平的差异性。方法:采用免疫组化En Vision法检测22例鼻咽癌患者原发灶和自身颈部淋巴结转移癌组织中E-Cadherin和β-catenin基因产物的表达水平。结果:(1)22例鼻咽癌患者淋巴结转移癌组织中的E-Cadherin阳性表达率(40.9%)显著低于22例原发灶组织中的表达水平(63.6%)(P<0.05);(2)β-catenin在原发灶和淋巴结转移癌组织中均有较高的表达(86.4%,90.9%),未显示有差异性(P>0.05);(3)原发灶与颈部淋巴结转移癌组织中癌细胞表达的E-Cadherin呈正相关(r=0.676,P<0.01);转移癌组织中E-Cadherin与β-catenin呈正相关(r=0.507,P<0.05)。结论:(1)在鼻咽癌组织中,导致癌细胞侵袭转移的一个重要因素可能是E-Cadherin的表达下调。(2)因某些原因积聚于细胞内的β-catenin可能在协同促进鼻咽癌细胞侵袭转移过程中起作用。(3)在肿瘤侵袭转移的过程中,E-Cadherin与β-catenin之间可能通过某些细胞信号通路连接进而相互调节,相互影响。Objective To study the E-Cadherin （E-Cad） and β-catenin （β-cat） expressions and their clinical significance in primary nasopharyngeal carcinoma （NPC） and self control cervical lymph node metastasis carcinoma. Method EnVision immunohistochemical method was performed in 22 cases self-control of NPC and cervical lymph node metastasis cancer. Results The expression of E-Cad in cervical lymph node metastasis carcinoma was significantly stronger than that in NPC （63.6% vs 40.9%, P 〈 0.05）. β-cat had the higher expression in both NPC and cervical lymph node metastasis carcinoma, but no significant differences between them （P 〉 0.05 ）. There were closely positive correlation between NPC and cervical lymph node metastasis carcinoma about the expression of E-Cad （r = 0.676,P 〈 0.01）, and between the expressions of E-Cad and β-cat in cervical lymph node metastasis carcinoma （r = 0.507, P 〈 0.05）. Conclusions The down-regulation of E-Cad and up-regulation of β-cat may play important roles in cancer invasion. E- Cad and β-cat may link through some sort of intracellular signal pathways and thus to influence each other.

关 键 词：鼻咽肿瘤 E-CADHERIN基因 Β-CATENIN基因 原发灶 自身颈部淋巴结转移癌组织 

分 类 号：R739.63[医药卫生—肿瘤]